CA
NZ
UK
AU
IND
US
Braveheart Bio is preparing for a $300 million initial public offering, a substantial infusion ofCapitalthat can accelerate growth and attract strategic partners. This influx of funds matters to investors as it will enable the company to advance its clinical programs and expand its research …
BrightSpring Health Services delivered a strong Q2 2026 performance, slashing $300 million of debt while posting $206 million of adjusted EBITDA and $87 million of net income. Analysts noted that the balance‑sheet improvement reduces refinancing risk and may support higherDividendpayouts or strategic acquisitions as …
Novo Nordisk experienced a dramatic 9% decline in its share price as news broke that the experimental heart medicine ziltivekimab did not achieve its intended efficacy inClinical Trials. This event marks a critical turning point for Novo Nordisk, which has heavily invested in its …
Zoetis (NYSE:ZTS) closed at $77.29, up $1.26, or 1.66%, on the session. That gain is noise against the trend. The shares are down 48.06% over theTrailing 12 Monthsand sit close to the floor of a 52-week range of $71.47 to $160.48, leaving a marketCapitalizationof …
Zimmer Biomet (NYSE:ZBH) closed at $93.93, down 1.08%, after a 2.25% fall the previous session, a two-day slide of roughly 3.3% into the week the company reports second-quarter results. The move is small in isolation, but it caps a year that has gone nowhere: …
At last closing, Waters (NYSE:WAT) completed its combination with Becton Dickinson's Biosciences and Diagnostic Solutions business, a transaction announced in July 2025 at an implied value of roughly $17.5 billion. The structure was a Reverse Morris Trust: BD separated the unit into a vehicle …
West Pharmaceutical Services (NYSE:WST) reported second-quarter 2026 results before the market opened on 23 July, and they were the strongest set the company has produced since pandemic-era demand unwound. Net sales of $872.3 million rose 13.8% as reported and 12.7% organically. AdjustedDiluted Earnings per …
STERIS plc (NYSE:STE) closed at $228.40 on Friday, down 1.22%, a second consecutive session of give-back after a sharp mid-summer run. The shares had climbed from $211.46 on 15 July to $234.83 on 29 July, roughly 11%, including a 5.5% jump on 28 July, …
Stryker (NYSE:SYK) reported second-quarter 2026 net sales of $6.6bn on 30 July, up 9.4% as reported and 9.0% organically, with adjusted earnings of $3.69 a share against a consensus near $3.49. On the surface this was the quarter the market had been waiting for …
Therapeutics (Nasdaq:SMMT). Shares of the Miami-based biotech closed at $13.02, down 3.12% and within eighty cents of the 52-week low of $12.25. The weakness sits awkwardly against the calendar: the FDA has set a goal action date of for ivonescimab in EGFR-mutated, non-squamous non-small …
Please wait processing your request...